ReVive Biotechnology

Re Vive Biotechnology

Nanotechnology, 4508 Southford Trce Dr, Champaign-Urbana, Illinois, 61822, United States, 1-10 Employees

revivebiotech.com

  • LinkedIn

Who is REVIVE BIOTECHNOLOGY

Revive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the Universit...

Read More

map
  • 4508 Southford Trce Dr, Champaign-Urbana, Illinois, 61822, United States Headquarters: 4508 Southford Trce Dr, Champaign-Urbana, Illinois, 61822, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Nanotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from REVIVE BIOTECHNOLOGY

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ReVive Biotechnology

Answer: ReVive Biotechnology's headquarters are located at 4508 Southford Trce Dr, Champaign-Urbana, Illinois, 61822, United States

Answer: ReVive Biotechnology's official website is https://revivebiotech.com

Answer: ReVive Biotechnology's revenue is Under $1 Million

Answer: ReVive Biotechnology's SIC: 7389

Answer: ReVive Biotechnology has 1-10 employees

Answer: ReVive Biotechnology is in Nanotechnology

Answer: ReVive Biotechnology contact info: Phone number: Website: https://revivebiotech.com

Answer: Revive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the University of Illinois, Urbana-Champaign, the team has access to state-of-the-art laboratories and facilities to carry out their research. With a goal of improving oxygen delivery to hypoxic tissues by utilizing innovative nanotechnology, research and development is currently focused on treatment for central retinal artery occlusion (CRAO) with potential future applications for additional ocular ischemic conditions, as well as hypoxic conditions in other organ systems. Pre-clinical studies have advanced through proof of concept and the team is now working through the regulatory process to achieve FDA approval for this revolutionary therapeutic.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access